ArticleFrontiers in genetics2022
Comprehensive Analysis of YTHDF1 Immune Infiltrates and ceRNA in Human Esophageal Carcinoma.
Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 24 citations in OpenAlex.
- ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and mCellular oncology (Dordrecht, Netherlands) · 2026Article
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Bioinformatics and experimental analysis revealed the cancer-promoting role of NCAPG2 in epithelial ovarian cancer.Frontiers in oncology · 2026Article
- RNA modification systems as therapeutic targets.Nature reviews. Drug discovery · 2026Review
- mActa pharmaceutica Sinica. B · 2025Review
- m6A-YTHDF1 Mediated Regulation of GRIN2D in Bladder Cancer Progression and Aerobic Glycolysis.Biochemical genetics · 2025Article
- Review
- Prognostic and immunotherapeutic significance of NCAPD2 in pan-cancer and its role in hepatocellular carcinoma progression via the AKT/GSK-3β signaling pathway.Scientific reports · 2025Article
- The potential of MCM8 as a biomarker in esophageal carcinoma: a comprehensive analysis integrating m6a methylation and angiogenesis.European journal of medical research · 2025Article
- HNRNPC as a pan-cancer biomarker and therapeutic target involved in tumor progression and immune regulation.Oncology research · 2025Article
- The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.Clinical and translational medicine · 2024Review
- YTHDF1 regulates immune cell infiltration in gastric cancer via interaction with p53.Experimental and therapeutic medicine · 2024Article
- Ferroptosis: a critical mechanism of NScience China. Life sciences · 2024Review
- Article
- m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer.Translational cancer research · 2023Article
- Wnt3a/YTHDF1 Regulated Oxaliplatin-Induced Neuropathic Pain Via TNF-α/IL-18 Expression in the Spinal Cord.Cellular and molecular neurobiology · 2023Article
- The diverse role of RNA methylation in esophageal cancer.Acta biochimica et biophysica Sinica · 2023Review
- The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer.Cell death discovery · 2023Review
- The function and clinical implication of YTHDF1 in the human system development and cancer.Biomarker research · 2023Review
- NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.